A Phase 3 interventional study of Neuronox and Placebo in Overactive Bladder, sponsored by Medy-Tox. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 13th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 34th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:
Mackay Medical College · Sites in Taiwan
Ages 30–100 · Women only
University of South Florida · Sites in United States
Ages 18+ · Women only
Walter Reed National Military Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 18 · Phase 4 10
First in 2005; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 84 across the 44 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 44 have an industry lead sponsor. The 10 most frequent:
Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Medy-Tox has 2 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
Drug: Neuronox
Normal saline, same volume with Experimental arm
Drug: Placebo
intradetrusor injection
Also known as: Meditoxin
intradetrusor injection
The change in the daily average UI (Urinary Incontinence) episodes
Time frame: 12 weeks
Ran from Aug 2019 to primary completion in Apr 2020, 7 months.
Of 26 industry-sponsored phase 3 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 16 months of starting (the median); a quarter within 11 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 33 studies reached it within 18 months; a quarter within 11 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A